[Intracerebral morphine therapy in cancer patients].
An overview of recent studies concerning opioids and their pharmacokinetics is presented. In the light of these findings it is shown that intracerebral administration may be justified. The authors experience with 63 cases is detailed: all cancer patients in the final stage. Initial dosage by the intraventricular route was 500 to 700 microgram-day but in one case twice daily injections of 1.200 microgram were needed. The dosage needed doubled over the observation period of 2 to 3 months. The mean length of survival was 75 days. Among complications nausea and vomiting were observed in 15 to 35% of the cases, sweating and pruritus in 15%, urinary retention in 15 to 20%. In some cases euphoria, motor excitement and hallucinations occurred. Chronic constipation was present in all cases. Two cases of meningitis were successfully treated by antibiotics. Pain relief was judged excellent or good in 75% of the cases. In 20% other analgesics had to be added to the treatment. In 5% the method failed.
Lajat
Y
Y
Centre d'Evaluation et de Traitement de la Douleur, Hôpital G. et R. Laënnec, Nantes.
Menegalli-Boggelli
D
D
Bensignor Le Henaff
M
M
Resche
F
F
D006801:Humans; D007276:Injections, Intraventricular; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000503:physiopathology*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology
D009020:Morphine
Morphinothérapie par voie intracérébrale chez le cancéreux.